Purely Off-Clamp Laparoscopic Partial Nephrectomy Stands the Test of Time: 15 Years Functional and Oncologic Outcomes from a Single Center Experience.
laparoscopy
long term outcomes
partial nephrectomy
renal cancer
survival
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
15 01 2023
15 01 2023
Historique:
received:
27
12
2022
revised:
09
01
2023
accepted:
12
01
2023
entrez:
20
1
2023
pubmed:
21
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Nephron-sparing surgery represents the gold standard treatment for organ-confined renal tumors. We present 15-years of outcomes after off-clamp laparoscopic partial nephrectomy (ocLPN). a retrospective analysis was performed on patients who underwent ocLPN between May 2001 and December 2005. Baseline demographic, clinical, pathologic, surgical, functional and survival data were collected. The Kaplan-Meier method evaluated group-specific oncologic outcomes at 5, 10 and 15 years and the log rank test assessed differences between groups. The same analysis investigated the probabilities of developing a significant renal function impairment (sRFI) and achieving We included 63 patients whose median tumor size was 3 cm (IQR:2-4). At 15 years, the chances of developing local recurrence, metachronous renal cancers or distant metastases were 2 ± 2%, 23 ± 6% and 17 ± 5%, respectively. Consequently, disease-free, cancer-specific and overall-survival probabilities were 68 ± 6%, 90 ± 4% and 72 ± 6%. MCRSS and UCISS well predicted oncologic outcomes. Overall, nine (14%) patients experienced an sRFI and 33 (52%) achieved At 15 years from ocLPN, most of patients will experience both excellent functional and oncologic outcomes.
Sections du résumé
BACKGROUND
Nephron-sparing surgery represents the gold standard treatment for organ-confined renal tumors. We present 15-years of outcomes after off-clamp laparoscopic partial nephrectomy (ocLPN).
METHODS
a retrospective analysis was performed on patients who underwent ocLPN between May 2001 and December 2005. Baseline demographic, clinical, pathologic, surgical, functional and survival data were collected. The Kaplan-Meier method evaluated group-specific oncologic outcomes at 5, 10 and 15 years and the log rank test assessed differences between groups. The same analysis investigated the probabilities of developing a significant renal function impairment (sRFI) and achieving
RESULTS
We included 63 patients whose median tumor size was 3 cm (IQR:2-4). At 15 years, the chances of developing local recurrence, metachronous renal cancers or distant metastases were 2 ± 2%, 23 ± 6% and 17 ± 5%, respectively. Consequently, disease-free, cancer-specific and overall-survival probabilities were 68 ± 6%, 90 ± 4% and 72 ± 6%. MCRSS and UCISS well predicted oncologic outcomes. Overall, nine (14%) patients experienced an sRFI and 33 (52%) achieved
CONCLUSIONS
At 15 years from ocLPN, most of patients will experience both excellent functional and oncologic outcomes.
Identifiants
pubmed: 36661741
pii: curroncol30010092
doi: 10.3390/curroncol30010092
pmc: PMC9858317
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1196-1205Références
Cancer. 2009 Apr 1;115(7):1465-71
pubmed: 19195042
BJU Int. 2018 Oct;122(4):618-626
pubmed: 29645344
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
J Urol. 2005 Apr;173(4):1098-101
pubmed: 15758709
Int J Urol. 2018 Jun;25(6):606-614
pubmed: 29663528
J Endourol. 2014 Jun;28(6):649-54
pubmed: 24405274
J Clin Oncol. 2014 Dec 20;32(36):4059-65
pubmed: 25403213
Cancers (Basel). 2022 Sep 13;14(18):
pubmed: 36139591
J Endourol. 2009 Sep;23(9):1473-8
pubmed: 19694532
J Endourol. 2017 Oct;31(10):976-984
pubmed: 28937805
Am J Kidney Dis. 2003 Jan;41(1):1-12
pubmed: 12500213
BJU Int. 2016 Jun;117(6):940-7
pubmed: 26696305
BJU Int. 2022 Feb;129(2):217-224
pubmed: 34086393
Minerva Urol Nefrol. 2020 Aug;72(4):482-489
pubmed: 32298069
Eur Urol. 2011 Jan;59(1):128-34
pubmed: 20971550
J Urol. 2012 Apr;187(4):1392-8
pubmed: 22341274
Int J Urol. 2019 Oct;26(10):985-991
pubmed: 31342589
Eur Urol Open Sci. 2022 Oct 28;46:75-81
pubmed: 36506251
J Urol. 2007 Feb;177(2):471-6
pubmed: 17222613
Eur Urol. 2022 Oct;82(4):399-410
pubmed: 35346519
J Urol. 2008 Mar;179(3):847-51; discussion 852
pubmed: 18221958
J Urol. 2013 Apr;189(4):1229-35
pubmed: 23085300
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Eur J Surg Oncol. 2016 Nov;42(11):1729-1735
pubmed: 27106494
Eur Urol. 2010 Oct;58(4):588-95
pubmed: 20674150
J Endourol. 2022 Nov 29;:
pubmed: 36367175
Urology. 2011 Oct;78(4):813-9
pubmed: 21802120
Eur Urol. 2015 Oct;68(4):632-40
pubmed: 25922273
J Urol. 2013 Jul;190(1):44-9
pubmed: 23306087
Eur J Surg Oncol. 2022 Oct 4;:
pubmed: 36216659
J Clin Oncol. 2001 Mar 15;19(6):1649-57
pubmed: 11250993
BJU Int. 2011 Jun;107(12):1886-92
pubmed: 21070570
Urology. 2007 Apr;69(4):642-5; discussion 645-6
pubmed: 17445641
Minerva Urol Nephrol. 2021 Dec;73(6):739-745
pubmed: 32573170
J Urol. 1995 May;153(5):1409-14
pubmed: 7714953
Eur Urol. 2010 Sep;58(3):340-5
pubmed: 20825756
Cancer. 2003 Apr 1;97(7):1663-71
pubmed: 12655523